相关实验视频

Updated: May 30, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

对复发性卵巢癌的PARPi再维持疗法的有效性

Yulin Wang¹, Yunjie Yang², Binghong Guo^1,3

¹State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Frontiers in oncology

|January 27, 2025

概括

与单独化疗相比,对敏感性复发性卵巢癌 (PSROC) 进行PARPi维护疗法的再给药显著改善了无进展的存活率. 在PARPi治疗之间超过6个月的间隔可能会提高疗效,特定的BRCA突变表明更好的结果.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
临床试验临床试验

背景情况:

有限的临床数据存在于对白金敏感性复发性卵巢癌 (PSROC) 进行PARPi维护治疗的重新管理.
研究PARPi重复治疗的疗效和预后因素对于优化患者的治疗结果至关重要.

研究的目的:

在PSROC患者中,评估PARPi再维持治疗与单独化疗的疗效.
为了确定与PARPi重复治疗在这个人群中的有效性相关的因素.

主要方法:

一项涉及201名PSROC患者的研究,他们之前接受了PARPi维持疗法.
倾向性得分匹配 (PSM) 分析比较了再PARPi治疗与单独的化疗.
评估了无进展生存 (PFS) 和预后因素.

主要成果:

在PSM小组中,再PARPi疗法在单独化疗 (6.5个月) 与化学疗法相比,显示出更高的PFS中位数 (10.0个月).
在PARPi疗法之间超过6个月的间隔与改善的PFS相关 (11.2个月与7.8个月相比).
特定的BRCA1生殖基因突变 (框架转移) 显示对PARPi重复治疗的反应明显更好.

结论:

对于PSROC患者来说,无论BRCA状态如何,PARPi再维持疗法都提供了潜在的生存益处.
优化治疗间隔和了解BRCA突变域可能会提高PARPi重复治疗的疗效.
用PARPi重复治疗被很好地容忍,这表明了有利的安全性.

关键词:

在 PARP 抑制剂.预后预后预后重新维护疗法的治疗.再发性卵巢癌的发生.这是BRCA突变的结构域.

更多相关视频

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...